3,4-Methylenedioxymethamphetamine (MDMA) interacts with therapeutic drugs on CYP3A by inhibition of pregnane X receptor (PXR) activation and catalytic enzyme inhibition
- 12 March 2011
- journal article
- Published by Elsevier in Toxicology Letters
- Vol. 203 (1) , 82-91
- https://doi.org/10.1016/j.toxlet.2011.03.007
Abstract
No abstract availableKeywords
This publication has 41 references indexed in Scilit:
- Differential Roles of Phase I and Phase II Enzymes in 3,4-Methylendioxymethamphetamine-Induced CytotoxicityDrug Metabolism and Disposition, 2010
- Species Differences in Mechanism-Based Inactivation of CYP3A in Humans, Rats and MiceDrug Metabolism and Pharmacokinetics, 2010
- Application and interpretation of hPXR screening data: Validation of reporter signal requirements for prediction of clinically relevant CYP3A4 inducersBiochemical Pharmacology, 2008
- Synthesis of novel ketoconazole derivatives as inhibitors of the human Pregnane X Receptor (PXR; NR1I2; also termed SXR, PAR)Bioorganic & Medicinal Chemistry Letters, 2008
- Influence of CYP2D6 polymorphism on 3,4-methylenedioxymethamphetamine (‘Ecstasy’) cytotoxicityPharmacogenetics and Genomics, 2006
- Human Pharmacology of MDMATherapeutic Drug Monitoring, 2004
- Non‐linear pharmacokinetics of MDMA (‘ecstasy’) in humansBritish Journal of Clinical Pharmacology, 2000
- SXR, a novel steroid and xenobioticsensing nuclear receptorGenes & Development, 1998
- Identification of a human nuclear receptor defines a new signaling pathway for CYP 3 A inductionProceedings of the National Academy of Sciences, 1998
- Ecstasy: A common cause of severe acute hepatotoxicityJournal of Hepatology, 1998